Immune Checkpoint Inhibitors in Thoracic Transplant Recipients: A Registry Initiative

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Recent reports indicate risk for fulminant myocarditis in non-transplant patients and severe, potentially fatal rejection in transplant recipients treated with ICIs. As the use of ICIs is expanding, there is an imperative to address gaps in our understanding of risk for ICI use in the post-transplant patient. The aim of this submission is to highlight a case series of thoracic transplant patients treated with ICIs and to introduce a clinical registry of ICI use.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (501) Source Type: research